N/A
Completed N=201
HD Mapping of Atrial Fibrillation in Asia Pacific
Source: ClinicalTrials.gov NCT04022954 ↗Enrolled (actual)
201
Serious AEs
2.5%
Results posted
Mar 2024
Primary outcomePrimary: Number of Participants With Acute Success of RF Ablation After Electroanatomical Mapping With HD Mapping Catheters. — 173 Participants
Summary
The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of, electroanatomical mapping with the market-released HD mapping catheters Inquiry™ AFocusII™ Double Loop and Advisor™ HD Grid, Sensor Enabled™ with the EnSite Cardiac Mapping System and the EnSite Automap module in subjects with AF in the real-world environment of the Asian population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Acute Success of RF Ablation After Electroanatomical Mapping With HD Mapping Catheters. |
173 | — |
| PRIMARY Number of Participants With Clinical Long-Term Success |
168 | — |
| PRIMARY Number of Participants With AAD-Free Long-Term Success |
104 | — |
| SECONDARY Overall Procedure Time |
152.9 | — |
| SECONDARY Radiofrequency (RF) Time |
35.9 | — |
| SECONDARY Fluoroscopy Time |
38.7 | — |
| SECONDARY Mapping Time Associated With Mapping Arrhythmia |
76.3 | — |
| SECONDARY Number of Mapping Points Collected |
9828.8 | — |
| SECONDARY Number of Mapping Points Used |
1962.4 | — |
| SECONDARY Number of Used Mapping Points Per Minute |
231.7 | — |
| SECONDARY Substrate Characteristics Identified |
181; 40; 1; 0; 4; 4 | — |
| SECONDARY Ablation Strategy(s) Used |
200; 110; 100; 93; 92; 98 | — |
Eligibility Criteria
Inclusion Criteria
- Subject must provide written informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule
- Subject must be over 18 years of age. (In Japan, the subject must be of 20 years of age or older)
- Subject is diagnosed with AF as defined by:
- Documented symptomatic paroxysmal AF defined as AF that terminates spontaneously or with intervention within 7 days of onset
- Documented symptomatic persistent AF defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 12 months
- Subject is indicated for cardiac electroanatomical mapping and RF ablation procedure to treat AF
- Subject is planned to have electroanatomical mapping performed with the HD mapping catheters under investigation
Exclusion Criteria
- Previous ablation or surgery in the left atria
- Implanted left atrial appendage occluder
- Implanted mitral or tricuspid valve replacement
- Implanted cardiac defibrillator (ICD)
- Participation in another clinical investigation that may confound the results of this study
- Pregnant or nursing
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
- Life expectancy less than 12 months
Data sourced from ClinicalTrials.gov (NCT04022954). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.